Vaccination against human genital papillomaviruses. More than a hypothesis

Human genital papillomaviruses are the necessary cause of cervical cancer. A prophylactic vaccine designed to prevent genital HPV disease by inducing virus neutralizing antibodies has been proposed. Studies on animal models have produced relevant data on the efficacy of HPV vaccine. The results of HPV clinical studies suggest that it will be possible to develop an effective vaccine. Nevertheless the number of subjects analyzed in the full text published clinical studies is still poor. Although a recently presented phase III study appears satisfied, it is probably necessary for a larger phase III study. Besides the choice of the geographical area for a very large clinical trial, there are different aspects to consider, such as the identification of the target population, identification of the endpoints, composition of the vaccine and marketing of the vaccine. Furthermore there are two open questions: the duration of protection and the behavioral modifications. All these issues are discussed in this review.

Papillomavirus, Cervical Cancer, Vaccination

[1] Ferlay J., Bray F., Pisani P., Parkin D. M. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer - Base n. 5 Version 2.0, Lyon, (France), IARC Press 2004.

[2] Parkin M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55, 74.

[3] Lowy D.R., Schiller J.T.: "Papillomaviruses: prophylactic vaccine prospects". Biochim. Biophys. Acta, 1998, 1423, Ml.

[4] Schiller J.T.: "Papillomavirus-like particle vaccines for cervical cancer". Mo!. Med. Today, 1999, 5, 209.

[5] Hilleman M.: "Overview of vaccinology with special reference to papillomavirus vaccines". J. Clin. Viral., 2000, 19, 79.

[6] Stern P.L., Brown M., Stacey S.N., Kitchener H.C., Hampson I., Abdel-Hady E.S., Moore J.V.: "Natural HPV immunity and vaccination strategies". J. Clin. Viral., 2000, 19, 57.

[7] Schiller J.T., Lowy D.R.: "Papillomavirus-like particle vaccines". J. Natl Cancer Inst. Monogr., 2000, 28, 50.

[8] Stanley M.A.: "Immunobiology of pap仆lomavirus infections". J. Reprod. Immun., 2001, 52, 45.

[9] Stanley M.: "Prognosic factors and new therapeutic approaches to cervical cancer". Virus Research, 2002, 89, 241.

[10] Galloway D.A.: "Papillomavirus vaccines in clinical trials". lancet Infect. Dis., 2003, 3, 469.

[11] Jansen KU., Shaw A.R.: "Human papillomavirus vaccine and prevention of cervical cancer". Annu. Rev. Med., 2004, 55, 319.

[12] De Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H.: "Classification of papillomaviruses". Virology, 2004, 324, 17.

[13] Munoz N., Bosch X.F., de Sanjose S., Hererro R., Castellsague X., Shah K.V. et al.: "Epidemiologic classification of human papillomavirus types associated with cervical cancer". N. Engl. J. Med., 2003, 384, 518.

[14] Munoz N., Bosch X.F., Castellsague X., Diaz M., De Sanjose S., Hammonda D. et al.: "Against which human papillomavirus types shall we vaccinate and screen? T he international perspective". Int. J. Cancer, 2004, 111, 278.

[15] Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T.: "Papillomavirus LI major capsid protein self-assembles into virus-like particles that are highly immunogenic". Proc. Natl. Acad Sci USA, 1992, 89, 12180.

[16] Harro C.D., Pang Y.YS., Roden R.B.S., Hildesheim A., Wang Z., Reynolds M.J. et al.: "Safety and immunogeneticy trial in adult volunteers of human papillomavirus 16, L 1 virus-like particle vaccine". ]NCI, 2001, 93, 284.

[17] Ault KA., Giuliano A.R., Edwards R.P., Tamms G., Kim L.L., Smith J.F. et al.: "A phase I study to evaluate a human papillomavirus (HPV) type 18 LI VLP vaccine". Vaccine, 2004, 22, 3004.

[18] Petry K.U., Scheffel D., Bode U., Gabrysiak T., Kochel H., Kupsch E. et al.: "Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions". Int. J. Cancer, 1994, 57, 836.

[19] Garzetti G.G., Ciavattini A., Butini L., Vecchi A., Montroni M.: "Cervical dysplasia in HIV-seropositive women: role of human papillomavirus infection and immune status". Gynecol. Obstet. Invest., 1995, 40, 52.

[20] Serraino D., Carrieri P., Pradier C., Bidoli E., Dorrucci M.. Ghetti E. et al.: "Risk of invasive cervical cancer among women with or at risk for HIV infection". Int. J. Cancer, 1999, 82, 334.

[21] Halpert R., Fruchter R.G., Sedlis A., Butt K., Boyce J.G., Sillman F.H.: "Human papillomavirus and lower genital neoplasia in renal transplant patients". Obstet. Gynecol., 1986, 68, 251.

[22] F razer l.H., Tindle R.W.: "Cell-mediated immunity to papillomaviruses". Papillomavirus Report, 1992, 3, 53.

[23] Coleman N., Birley H.D., Renton A.M., Hanna N.F., Ryait B.K., Byrne M. et al.: "Immunological events in regressing genital warts". Am. J Clin. Pathol., 1994, 102, 768.

[24] Greenstone H.L., Nieland J.D., De Visser K.E., De Bruijn M.L.H., Kirnbauer R., Roden R.B.S. et al.: "Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model". Proc. Natl. Acad Sci USA, 1998, 95, 1800.

[25] Schafer K., Muller M., Faath S., Henn A., Osen W., Zentgraf H. et al.: "Immune response to human papillomavirus 16 L 1 E7 chimeric viruslike particles: induction of cytotoxic T cells and specific tumor protection". Int. J. Cancer, 1999, 81, 881.

[26] Jochmus I., Schafer K., Faath S., Muller M., Gissmann L.: "Chimeric virus-like particles of the human papillomavirus type 16 (HPV16) as a prophylactic and therapeutic vaccine". Arch. Med. Res., 1999, 30, 269.

[27] Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G. et al.: "Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection". J. Virol., 1995, 69, 3959.

[28] Jansen KU., Rosolowsky M., Schultz L.D., Markus H.Z., Cook J.C., Donnelly J.J. et al.: "Vaccination with yest-expressed cottontail rabbit papillomavirus (CRPV) viruslike particles protects rabbits from CRPV induced papilloma formation". Vaccine, 1995, 13, 1509.

[29] Suzich J.A., Ghim S.J., Palmer-Hill F.J., White WI., Tamura J.K., Bell J.A. et al.: "Systemic immunization with papillomavirus LI protem completely prevents the development of viral mucosal papillomas". Proc. Natl. Acad. Sci USA, 1995, 92, 11553.

[30] Kirnbauer R., Chandrachud L., O'Neil B., Wagner E., Grindlay G., Arnmstrong A. et al.: "Virus-like particles of bovine papillomav1rus type 4 in prophylactic and therapeutic immunization". Virology, 1996, 219, 37.

[31] Christensen N.D., Reed C.A., Cladel N.M., Han R., Hreider J.W.: "Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus". J. Virol., 1996, 70, 960.

[32] Lowe R.S., Brown D.R., Bryan J.T., Cook J.C., George H.A., Hofmann K.J. et al.: "Human papillomavirus type 11 (HPV 11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV 11 virus-like particles expressed in yeast". J. Infect. Dis., 1997,176, 1141.

[33] Brown D.R., Bryan J.T., Schroeder J.M., Robinson T., Fife K.H., Wheeler C.M. et al.: "Neutralization of human papillomavirus type 11 (HPV 11) by serum from women vaccinated with yeast-derived HPV l lLI virus-like particles: correlation with competitive radioimmunoassay titer". J. Infect. Dis., 2001, 184, 1183.

[34] Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B. et al.: "A controlled trial of a human papillomavirus type 16 vaccine". N. Engl. J. Med., 2002, 347, 1645.

[35] Brown D.R., Fife K.H., Wheeler C.M., Koutsky L.A., Lupinacci L.M., Railkar R. et al.: "Early assessment of the efficacy of a human papillomavirus type 16LI virus-like particle vaccine". Vaccine, 2004, 22, 2936.

[36] Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A. et al.: "Efficacy of a bilavent virus-like particle vaccme m prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial". Lancet, 2004, 363, 1757.

[37] Villa L., Costa R., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R.: "Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) LI virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial". Lancet Oneal., 2005, 6, 271.

[38] Fife K.H., Wheeler C.M., Koutsky L.A., Barr E., Brown D.R., Schiff M.A. et al.: "Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women". Vaccine, 2004, 22, 2943.

[39] Ault K.: "Prophylactic use of quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) LI virus-like particle (VLP) vaccine reduces cervical intraepithelial neoplasia (CIN) II-III and adenocarcinoma in situ (AIS) risk" (abstract). 13th European Cancer Conference (ECCO) Paris, 30 October-3 November, 2005.

[40] Paavonen J., Halttunen M., Hansson B.G., Nieminen P., Rostila T., Lehtinen M.: "Prerequisites for human papillomavirus vaccine trial: results of feasib山ty studies". J. Clin. Vim/., 2000, 19, 25.

[41] Lehtinen M., Kibur M., Luostarinen T., Anttila A., Pukkala E.: "Prospects for phase III-IV HPV vaccination trials in the Nordic countries and Estonia". J. Clin. Viral., 2000, 19, 113.

[42] Plummer M., Franceschi S.: "Strategies for HPV prevention". Virus Res., 2002, 89, 285.

[43] Lazcano E., Rivera L., Arillo E., Salmeon J., Hernandez M., Munoz M.: "Acceptability of an HPY vaccine among women in Cuemavaca Mexico (Abstract 446)". 18•h International Papillomavirus Conference, Barcelona, 2000.

[44] World Health Organization: "Cervical cancer control in developing countries. Memorandum from a WHO meeting". Bull WorId Health Organ, 1996, 74, 345.

[45] Communicable Disease Reports: "Sexually transmitted infections quarterly report: anogenital warts and HSY infection in England and Wales" Commun Dis. Rep., 2001, 11, 11.

[46] Gillison M.L., Shah K.Y.: "Role of mucosal human papillomavirus in nongenital cancers (Monograph 31)". INCi, 2003, 57.

[47] Geijersstam Y., Kibur M., Wang Z., Koskela P., Pukkala E., Schiller J. et al.: "Stability over time of serum antibody levels to human papillomavirus type 16". J. Infect. Dis., 1998, 177, 1710.

[48] Garnett G.P., Waddell H.C.: "Public health paradoxes and the epidemiological impact of an HPV vaccine". J. Clin. Viral., 2000, 19, 101.